NCT06481774

Brief Summary

The purpose of this research is to evaluate a novel, integrated approach to providing navigation services to improve cancer outcomes and quality of life.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
375

participants targeted

Target at P75+ for not_applicable cancer

Timeline
14mo left

Started Jul 2024

Typical duration for not_applicable cancer

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress62%
Jul 2024Jun 2027

First Submitted

Initial submission to the registry

June 24, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 1, 2024

Completed
29 days until next milestone

Study Start

First participant enrolled

July 30, 2024

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2027

Last Updated

September 29, 2025

Status Verified

September 1, 2025

Enrollment Period

2.9 years

First QC Date

June 24, 2024

Last Update Submit

September 26, 2025

Conditions

Keywords

Patient navigators

Outcome Measures

Primary Outcomes (2)

  • Participant improvement as measured by participant distress screening tool

    Participant distress screening assessment tool is a list of questionnaire with a scale from 0-10, where 0 is none and 10 is extreme distress

    4 months

  • Quality of life as measured by PHQ-9 Patient Depression Questionnaire

    Intepretation for PHQ-9 Patient Depression Questionnaire is based on the final score ranging from 1-27, 1-4 is minimal depression, 5-9 is mild, 10-14 is moderate, 15-19 is moderately severe, 20-27 is severe depression

    4 months

Secondary Outcomes (2)

  • The number of social needs as measured by HRSN(Health related social need) questionnaire

    4 months

  • Rate of patient satisfaction as measured by cancer care survey

    4 months

Study Arms (1)

Patient Navigation Services

EXPERIMENTAL

Following the consent process, participant will have access to a Patient Navigator, who will serve as a resource for during the time in the study to help navigate and get connected to local resources. The Patient Navigator will keep track of the kinds of support services and referrals provided. The Patient Navigator will contact the participant in 4 months to reassess current needs, quality of life, and areas where additional support is needed.

Behavioral: CONNECT platform

Interventions

CONNECT platform provides access to participant information across the 5 participant sites to facilitate a more holistic approach to addressing participant needs. It is the use of this cloud-based, HIPAA compliant platform that constitutes the uniqueness of this behavioral intervention.

Patient Navigation Services

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • First, investigators will identify individuals who have either had a cancer screening with a suspicious finding (ie. requires diagnostic follow-up) or those individuals who are referred to the UH Seidman Diagnostic Clinic (led by Co-I Hoehn).
  • Within that group, investigators will recruit those who identify as African American, Hispanic, or living in a prioritized geography as defined by zip code ADI\>=75%ile for state

You may not qualify if:

  • Any participant who is not willing or able to complete an informed consent form will not be eligible for this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Case Comprehensive Cancer Center

Cleveland, Ohio, 44106, United States

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Erika Trapl, PhD

    Case Western Reserve University, Case Comprehensive Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 24, 2024

First Posted

July 1, 2024

Study Start

July 30, 2024

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2027

Last Updated

September 29, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share

As a recipient of Merck Foundation funding, investigators are obligated to collect "harmonized metrics" for program participants. This data is shared back (at the individual level) with the National Program Office. There is no PHI in this dataset, and there is no personal identifying information that is shared. The data is not shared beyond the NPO; all data shared by the NPO is aggregated and not identifiable. Additionally, investigator does not intend to share IPD with anyone outside of the NPO

Time Frame
Data is shared with the NPO on a quarterly basis
Access Criteria
Data is only shared with the NPO

Locations